http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-100730267-B1

Outgoing Links

Predicate Object
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-416
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D405-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D231-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-06
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D231-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-416
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D405-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-02
filingDate 2003-12-08-04:00^^<http://www.w3.org/2001/XMLSchema#date>
grantDate 2007-06-20-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationDate 2007-06-20-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber KR-100730267-B1
titleOfInvention 2- (1H-indazol-6-ylamino) -benzamide compound as a protein kinase inhibitor useful for treating ophthalmic diseases
abstract The present invention relates to indazole compounds that modulate and / or inhibit the activity of eye diseases and certain protein kinases. These compounds and pharmaceutical compositions containing them may mediate tyrosine kinase signal transduction and thus modulate and / or inhibit unwanted cell proliferation. The present invention also provides therapeutic or prophylactic use of a pharmaceutical composition containing the compound, and disease states associated with ocular diseases, cancer and other unwanted angiogenesis and / or cell proliferation by administering an effective amount of the compound, For example, it relates to methods of treating diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis and psoriasis.n n n Indazole compounds, eye diseases, protein kinase inhibitors, protein kinase receptors
priorityDate 2002-12-19-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-0102369-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-0153268-A2
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID154439447
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID23577851
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID423146226
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID410435319
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID466748503
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID23577839
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID800907
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID467538654
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID420260800
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID23577842
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID432993970
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID406941062

Total number of triples: 48.